1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations

2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer's
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter's Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics

4. Global Oncology Nutrition Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis

5. Global Oncology Nutrition Analysis 2017-2021 and Forecast 2022-2032, By Cancer Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Bn) Analysis By Cancer Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Cancer Type, 2022-2032
5.3.1. Head & Neck
5.3.2. Stomach & Gastrointestinal
5.3.3. Pancreatic
5.3.4. Breast
5.3.5. Liver
5.3.6. Other Cancer Types
5.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Cancer Type, 2022-2032

6. Global Oncology Nutrition Analysis 2017-2021 and Forecast 2022-2032, By End-Use
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Bn) Analysis By End-Use, 2017-2021
6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By End-Use, 2022-2032
6.3.1. Hospitals
6.3.2. Home Care
6.3.3. Other End-Uses
6.4. Y-o-Y Growth Trend Analysis By End-Use, 2017-2021
6.5. Absolute $ Opportunity Analysis By End-Use, 2022-2032

7. Global Oncology Nutrition Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region

8. North America Oncology Nutrition Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Cancer Type
8.2.3. By End-Use
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Cancer Type
8.3.3. By End-Use
8.4. Key Takeaways

9. Latin America Oncology Nutrition Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Argentina
9.2.1.4. Chile
9.2.1.5. Peru
9.2.1.6. Rest of Latin America
9.2.2. By Cancer Type
9.2.3. By End-Use
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Cancer Type
9.3.3. By End-Use
9.4. Key Takeaways

10. Europe Oncology Nutrition Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. Italy
10.2.1.3. France
10.2.1.4. U.K.
10.2.1.5. Spain
10.2.1.6. Russia
10.2.1.7. BENELUX
10.2.1.8. Rest of Europe
10.2.2. By Cancer Type
10.2.3. By End-Use
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Cancer Type
10.3.3. By End-Use
10.4. Key Takeaways

11. Asia Pacific Oncology Nutrition Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Rest of Asia Pacific
11.2.2. By Cancer Type
11.2.3. By End-Use
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Cancer Type
11.3.3. By End-Use
11.4. Key Takeaways

12. MEA Oncology Nutrition Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Turkey
12.2.1.4. Rest of MEA
12.2.2. By Cancer Type
12.2.3. By End-Use
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Cancer Type
12.3.3. By End-Use
12.4. Key Takeaways

13. Key Countries Oncology Nutrition Analysis
13.1. U.S.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Cancer Type
13.1.2.2. By End-Use
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Cancer Type
13.2.2.2. By End-Use
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Cancer Type
13.3.2.2. By End-Use
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Cancer Type
13.4.2.2. By End-Use
13.5. Argentina
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Cancer Type
13.5.2.2. By End-Use
13.6. Chile
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Cancer Type
13.6.2.2. By End-Use
13.7. Peru
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Cancer Type
13.7.2.2. By End-Use
13.8. Germany
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Cancer Type
13.8.2.2. By End-Use
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Cancer Type
13.9.2.2. By End-Use
13.10. France
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Cancer Type
13.10.2.2. By End-Use
13.11. U.K.
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Cancer Type
13.11.2.2. By End-Use
13.12. Spain
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Cancer Type
13.12.2.2. By End-Use
13.13. Russia
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Cancer Type
13.13.2.2. By End-Use
13.14. BENELUX
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Cancer Type
13.14.2.2. By End-Use
13.15. China
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Cancer Type
13.15.2.2. By End-Use
13.16. Japan
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Cancer Type
13.16.2.2. By End-Use
13.17. South Korea
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Cancer Type
13.17.2.2. By End-Use
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Cancer Type
13.18.2.2. By End-Use
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Cancer Type
13.19.2.2. By End-Use
13.20. Turkey
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2021
13.20.2.1. By Cancer Type
13.20.2.2. By End-Use

14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Cancer Type
14.3.3. By End-Use

15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Abbott Laboratories
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.1.5.2. Product Strategy
15.1.1.5.3. Channel Strategy
15.1.2. B. Braun Melsungen AG
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.2.5.2. Product Strategy
15.1.2.5.3. Channel Strategy
15.1.3. Baxter International Inc.
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.3.5.2. Product Strategy
15.1.3.5.3. Channel Strategy
15.1.4. Fresenius Kabi AG
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.4.5.2. Product Strategy
15.1.4.5.3. Channel Strategy
15.1.5. Hormel Foods Corporation
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.5.5.2. Product Strategy
15.1.5.5.3. Channel Strategy
15.1.6. Mead Johnson & Company LLC
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.6.5.2. Product Strategy
15.1.6.5.3. Channel Strategy
15.1.7. Nestle S.A.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.7.5.2. Product Strategy
15.1.7.5.3. Channel Strategy
15.1.8. Pfizer Inc.
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.8.5.2. Product Strategy
15.1.8.5.3. Channel Strategy

16. Assumptions & Acronyms Used
17. Research Methodology

List of Figures

Figure 1: Global Oncology Nutrition Value (US$ Bn) by Cancer Type, 2022-2032

Figure 2: Global Oncology Nutrition Value (US$ Bn) by End-Use, 2022-2032

Figure 3: Global Oncology Nutrition Value (US$ Bn) by Region, 2022-2032

Figure 4: Global Oncology Nutrition Value (US$ Bn) Analysis by Region, 2017-2032

Figure 5: Global Oncology Nutrition Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 6: Global Oncology Nutrition Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 7: Global Oncology Nutrition Value (US$ Bn) Analysis by Cancer Type, 2017-2032

Figure 8: Global Oncology Nutrition Value Share (%) and BPS Analysis by Cancer Type, 2022-2032

Figure 9: Global Oncology Nutrition Y-o-Y Growth (%) Projections by Cancer Type, 2022-2032

Figure 10: Global Oncology Nutrition Value (US$ Bn) Analysis by End-Use, 2017-2032

Figure 11: Global Oncology Nutrition Value Share (%) and BPS Analysis by End-Use, 2022-2032

Figure 12: Global Oncology Nutrition Y-o-Y Growth (%) Projections by End-Use, 2022-2032

Figure 13: Global Oncology Nutrition Attractiveness by Cancer Type, 2022-2032

Figure 14: Global Oncology Nutrition Attractiveness by End-Use, 2022-2032

Figure 15: Global Oncology Nutrition Attractiveness by Region, 2022-2032

Figure 16: North America Oncology Nutrition Value (US$ Bn) by Cancer Type, 2022-2032

Figure 17: North America Oncology Nutrition Value (US$ Bn) by End-Use, 2022-2032

Figure 18: North America Oncology Nutrition Value (US$ Bn) by Country, 2022-2032

Figure 19: North America Oncology Nutrition Value (US$ Bn) Analysis by Country, 2017-2032

Figure 20: North America Oncology Nutrition Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 21: North America Oncology Nutrition Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 22: North America Oncology Nutrition Value (US$ Bn) Analysis by Cancer Type, 2017-2032

Figure 23: North America Oncology Nutrition Value Share (%) and BPS Analysis by Cancer Type, 2022-2032

Figure 24: North America Oncology Nutrition Y-o-Y Growth (%) Projections by Cancer Type, 2022-2032

Figure 25: North America Oncology Nutrition Value (US$ Bn) Analysis by End-Use, 2017-2032

Figure 26: North America Oncology Nutrition Value Share (%) and BPS Analysis by End-Use, 2022-2032

Figure 27: North America Oncology Nutrition Y-o-Y Growth (%) Projections by End-Use, 2022-2032

Figure 28: North America Oncology Nutrition Attractiveness by Cancer Type, 2022-2032

Figure 29: North America Oncology Nutrition Attractiveness by End-Use, 2022-2032

Figure 30: North America Oncology Nutrition Attractiveness by Country, 2022-2032

Figure 31: Latin America Oncology Nutrition Value (US$ Bn) by Cancer Type, 2022-2032

Figure 32: Latin America Oncology Nutrition Value (US$ Bn) by End-Use, 2022-2032

Figure 33: Latin America Oncology Nutrition Value (US$ Bn) by Country, 2022-2032

Figure 34: Latin America Oncology Nutrition Value (US$ Bn) Analysis by Country, 2017-2032

Figure 35: Latin America Oncology Nutrition Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 36: Latin America Oncology Nutrition Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 37: Latin America Oncology Nutrition Value (US$ Bn) Analysis by Cancer Type, 2017-2032

Figure 38: Latin America Oncology Nutrition Value Share (%) and BPS Analysis by Cancer Type, 2022-2032

Figure 39: Latin America Oncology Nutrition Y-o-Y Growth (%) Projections by Cancer Type, 2022-2032

Figure 40: Latin America Oncology Nutrition Value (US$ Bn) Analysis by End-Use, 2017-2032

Figure 41: Latin America Oncology Nutrition Value Share (%) and BPS Analysis by End-Use, 2022-2032

Figure 42: Latin America Oncology Nutrition Y-o-Y Growth (%) Projections by End-Use, 2022-2032

Figure 43: Latin America Oncology Nutrition Attractiveness by Cancer Type, 2022-2032

Figure 44: Latin America Oncology Nutrition Attractiveness by End-Use, 2022-2032

Figure 45: Latin America Oncology Nutrition Attractiveness by Country, 2022-2032

Figure 46: Europe Oncology Nutrition Value (US$ Bn) by Cancer Type, 2022-2032

Figure 47: Europe Oncology Nutrition Value (US$ Bn) by End-Use, 2022-2032

Figure 48: Europe Oncology Nutrition Value (US$ Bn) by Country, 2022-2032

Figure 49: Europe Oncology Nutrition Value (US$ Bn) Analysis by Country, 2017-2032

Figure 50: Europe Oncology Nutrition Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 51: Europe Oncology Nutrition Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 52: Europe Oncology Nutrition Value (US$ Bn) Analysis by Cancer Type, 2017-2032

Figure 53: Europe Oncology Nutrition Value Share (%) and BPS Analysis by Cancer Type, 2022-2032

Figure 54: Europe Oncology Nutrition Y-o-Y Growth (%) Projections by Cancer Type, 2022-2032

Figure 55: Europe Oncology Nutrition Value (US$ Bn) Analysis by End-Use, 2017-2032

Figure 56: Europe Oncology Nutrition Value Share (%) and BPS Analysis by End-Use, 2022-2032

Figure 57: Europe Oncology Nutrition Y-o-Y Growth (%) Projections by End-Use, 2022-2032

Figure 58: Europe Oncology Nutrition Attractiveness by Cancer Type, 2022-2032

Figure 59: Europe Oncology Nutrition Attractiveness by End-Use, 2022-2032

Figure 60: Europe Oncology Nutrition Attractiveness by Country, 2022-2032

Figure 61: Asia Pacific Oncology Nutrition Value (US$ Bn) by Cancer Type, 2022-2032

Figure 62: Asia Pacific Oncology Nutrition Value (US$ Bn) by End-Use, 2022-2032

Figure 63: Asia Pacific Oncology Nutrition Value (US$ Bn) by Country, 2022-2032

Figure 64: Asia Pacific Oncology Nutrition Value (US$ Bn) Analysis by Country, 2017-2032

Figure 65: Asia Pacific Oncology Nutrition Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 66: Asia Pacific Oncology Nutrition Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 67: Asia Pacific Oncology Nutrition Value (US$ Bn) Analysis by Cancer Type, 2017-2032

Figure 68: Asia Pacific Oncology Nutrition Value Share (%) and BPS Analysis by Cancer Type, 2022-2032

Figure 69: Asia Pacific Oncology Nutrition Y-o-Y Growth (%) Projections by Cancer Type, 2022-2032

Figure 70: Asia Pacific Oncology Nutrition Value (US$ Bn) Analysis by End-Use, 2017-2032

Figure 71: Asia Pacific Oncology Nutrition Value Share (%) and BPS Analysis by End-Use, 2022-2032

Figure 72: Asia Pacific Oncology Nutrition Y-o-Y Growth (%) Projections by End-Use, 2022-2032

Figure 73: Asia Pacific Oncology Nutrition Attractiveness by Cancer Type, 2022-2032

Figure 74: Asia Pacific Oncology Nutrition Attractiveness by End-Use, 2022-2032

Figure 75: Asia Pacific Oncology Nutrition Attractiveness by Country, 2022-2032

Figure 76: MEA Oncology Nutrition Value (US$ Bn) by Cancer Type, 2022-2032

Figure 77: MEA Oncology Nutrition Value (US$ Bn) by End-Use, 2022-2032

Figure 78: MEA Oncology Nutrition Value (US$ Bn) by Country, 2022-2032

Figure 79: MEA Oncology Nutrition Value (US$ Bn) Analysis by Country, 2017-2032

Figure 80: MEA Oncology Nutrition Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 81: MEA Oncology Nutrition Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 82: MEA Oncology Nutrition Value (US$ Bn) Analysis by Cancer Type, 2017-2032

Figure 83: MEA Oncology Nutrition Value Share (%) and BPS Analysis by Cancer Type, 2022-2032

Figure 84: MEA Oncology Nutrition Y-o-Y Growth (%) Projections by Cancer Type, 2022-2032

Figure 85: MEA Oncology Nutrition Value (US$ Bn) Analysis by End-Use, 2017-2032

Figure 86: MEA Oncology Nutrition Value Share (%) and BPS Analysis by End-Use, 2022-2032

Figure 87: MEA Oncology Nutrition Y-o-Y Growth (%) Projections by End-Use, 2022-2032

Figure 88: MEA Oncology Nutrition Attractiveness by Cancer Type, 2022-2032

Figure 89: MEA Oncology Nutrition Attractiveness by End-Use, 2022-2032

Figure 90: MEA Oncology Nutrition Attractiveness by Country, 2022-2032

List of Tables

Table 1: Global Oncology Nutrition Value (US$ Bn) Forecast by Region, 2017-2032

Table 2: Global Oncology Nutrition Value (US$ Bn) Forecast by Cancer Type, 2017-2032

Table 3: Global Oncology Nutrition Value (US$ Bn) Forecast by End-Use, 2017-2032

Table 4: North America Oncology Nutrition Value (US$ Bn) Forecast by Country, 2017-2032

Table 5: North America Oncology Nutrition Value (US$ Bn) Forecast by Cancer Type, 2017-2032

Table 6: North America Oncology Nutrition Value (US$ Bn) Forecast by End-Use, 2017-2032

Table 7: Latin America Oncology Nutrition Value (US$ Bn) Forecast by Country, 2017-2032

Table 8: Latin America Oncology Nutrition Value (US$ Bn) Forecast by Cancer Type, 2017-2032

Table 9: Latin America Oncology Nutrition Value (US$ Bn) Forecast by End-Use, 2017-2032

Table 10: Europe Oncology Nutrition Value (US$ Bn) Forecast by Country, 2017-2032

Table 11: Europe Oncology Nutrition Value (US$ Bn) Forecast by Cancer Type, 2017-2032

Table 12: Europe Oncology Nutrition Value (US$ Bn) Forecast by End-Use, 2017-2032

Table 13: Asia Pacific Oncology Nutrition Value (US$ Bn) Forecast by Country, 2017-2032

Table 14: Asia Pacific Oncology Nutrition Value (US$ Bn) Forecast by Cancer Type, 2017-2032

Table 15: Asia Pacific Oncology Nutrition Value (US$ Bn) Forecast by End-Use, 2017-2032

Table 16: MEA Oncology Nutrition Value (US$ Bn) Forecast by Country, 2017-2032

Table 17: MEA Oncology Nutrition Value (US$ Bn) Forecast by Cancer Type, 2017-2032

Table 18: MEA Oncology Nutrition Value (US$ Bn) Forecast by End-Use, 2017-2032

List of Companies

FMC Corporation
Danone India
Abbott
Aceto
B. Braun Melsungen AG
Baxter
Fresenius Kabi AG
Global Health Products, Inc.
Hormel Foods Corporation
Mead Johnson & Company, LLC
Meiji Holdings Co., Ltd
Nestlé S.A.
BioSig Technologies, Inc.
Auris Health, Inc.